



February 9, 2023

Consolidated Financial Results for the Third Quarter Ended December 31, 2022 Terumo Corporation [IFRS]

Company name: TERUMO CORPORATION
 Listing: Tokyo Stock Exchange
 Securities code: 4543
 URL: <https://www.terumo.com/>
 Representative: Shinjiro Sato, President and CEO
 Inquiries: Kenichi Hata, General Manager, Investor Relations Dept.
 Telephone: +81-3-6742-8550
 Scheduled date to file quarterly securities report: February 13, 2023
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on quarterly financial results: Yes
 Holding of quarterly financial results briefing: Yes (for Securities analysts, Institutional investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended December 31, 2022 (from April 1, 2022 to December 31, 2022)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit for the period		Profit attributable to owners of the parent		Total comprehensive income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended												
December 31, 2022	617,993	18.1	93,514	(1.0)	92,100	(1.0)	70,180	(2.1)	70,180	(2.1)	139,144	36.4
December 31, 2021	523,482	16.7	94,455	25.5	93,044	24.2	71,696	22.6	71,696	22.3	102,045	182.9

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2022	93.25	93.21
December 31, 2021	94.82	94.76

(Note) Adjusted operating profit December 2022: 109,607 million yen December 2021: 107,157 million yen

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
December 31, 2022	1,543,470	1,073,711	1,073,711	69.6
March 31, 2022	1,473,693	1,012,313	1,012,313	68.7

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2022	—	16.00	—	18.00	34.00
Fiscal year ending March 31, 2023	—	19.00	—		
Fiscal year ending March 31, 2023 (Forecast)				21.00	40.00

(Note) Revision from the dividend forecast, which is published in the most recent: Yes

The company revises fiscal year-end dividends per share for the fiscal year ending March 2023 from 19yen to 21yen.

Please refer to the February 9, 2023 press release, “Notice Concerning Revision of the Year-end Dividend Forecast for Fiscal Year Ending March 31, 2023 (Dividend Increase).”

3. Consolidated Forecast for the Fiscal Year Ending March, 2023 (From April 1, 2022 to March 31, 2023)

(Percentages indicate year-on-year changes.)

	Revenue		Adjusted operating profit		Operating profit		Profit for the year attributable to owners of the parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March, 2023	815,000	15.9	143,000	6.4	122,000	5.2	91,500	3.0	121.90

(Note) Revision of forecast for the fiscal year ending March, 2023: Yes

Regarding the forecast for cumulative consolidated earnings for the fiscal year, please refer to the February 9th, 2023 press release “Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023 (FY2022)”.

- Assumed exchange rate for fiscal year ending March, 2023: USD1=JPY135, EUR1=JPY140
- Assumed exchange rate for fourth quarter of fiscal year ending March, 2023: USD1=JPY130, EUR1=JPY140

*Notes

- (1) Changes in significant subsidiaries during the current quarterly consolidated cumulative period (changes in specified subsidiaries resulting in changes in the scope of consolidation): Yes
 New — Company (Company Name) —, Excluded 1 Company (Company Name) Terumo Yamaguchi D&D Corporation

As of October 1, 2022, Terumo Yamaguchi D&D Corporation is excluded from the scope of consolidation due to its extinguishment following the exclusion of an absorption-type merger in which Terumo Yamaguchi Corporation, the Company's subsidiary, was the surviving company and Terumo Yamaguchi D&D Corporation was the extinguished company.

- (2) Changes in accounting policies and changes in accounting estimates

- (i) Changes in accounting policies required by IFRS: None
 (ii) Changes in accounting policies other than (i): None
 (iii) Changes in accounting estimates: None

- (3) Number of shares outstanding (common stock)

(i) Number of outstanding shares at the end of the period (including treasury shares)	As of December 31, 2022	759,521,040 shares	As of March 31, 2022	759,521,040 shares
(ii) Treasury shares at the end of the period	As of December 31, 2022	14,926,739 shares	As of March 31, 2022	3,194,976 shares
(iii) Average number of shares during the period (cumulative quarterly)	Nine months ended December 31, 2022	752,618,446 shares	Nine months ended December 31, 2021	756,170,427 shares

* Quarterly financial statements are not subject to quarterly reviews by certified accountants or audit firms.

* Explanation on appropriate use of financial results forecasts and other special notes

- Forward-looking statements, including earnings forecasts, contained in these disclosure materials are based on currently available information and assumptions believed to be reasonable by management. This is not a promise or guarantee by Terumo that it will achieve these goals. In addition, actual results may differ significantly due to several factors. For the assumptions that are the premise of the earnings forecast and the precautions for using the earnings forecast, refer to [Attachment], page 5, "1. Overview of Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023 (3) Forecasts, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2023".
- Adjusted operating profit factors out amortization expense for intangible assets obtained during acquisitions and one-off income and expenses from operating profit. In addition, adjusted operating profit is consistent with segment profit. We are disclosing adjusted operating profit as we are using it as a performance indicator.

○ Table of contents of attached materials

1. Overview of Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023	2
(1) Overview of Consolidated Business Results	2
(2) Overview of Consolidated Statement of Financial Position.....	5
(3) Forecasts, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2023	5
2. Condensed Consolidated Financial Statements	6
(1) Condensed Consolidated Statement of Financial Position	6
(2) Condensed Consolidated Statement of Profit or Loss and Condensed Consolidated Statement of Comprehensive Income	8
(3) Condensed Consolidated Statement of Changes in Equity.....	10
(4) Notes Pertaining to Condensed Consolidated Financial Statements	11
(i) Going Concern Assumption.....	11
(ii) Segment Information	11
(iii) Impairment of Non-Financial Assets	14
(iv) Subsequent Events	14

1. Overview of Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023

(1) Overview of Consolidated Business Results

In the first nine months of the current fiscal year (from April 1, 2022 to December 31, 2022), the Group's sales trended strongly in general amid the recovery in medical demand which had declined in the previous fiscal year due to the COVID-19 pandemic, as well as due to the positive impact by yen depreciation.

Adjusted operating profit rose as higher revenue, hikes to selling prices, and stricter measures to control costs partially offset increases in manufacturing costs caused by inflation.

Financial results for the first nine months are as follows:

(Unit: Millions of yen)

	For the nine months ended December 31, 2021	For the nine months ended December 31, 2022	Growth (%)	Growth excluding impact of FX translations (%)
Revenue	523,482	617,993	18.1	5.6
Gross profit	278,841	318,347	14.2	3.2
Adjusted operating profit	107,157	109,607	2.3	(5.5)
Operating profit	94,455	93,514	(1.0)	(6.0)
Profit before tax	93,044	92,100	(1.0)	—
Profit for the period	71,696	70,180	(2.1)	—
Profit for the period attributable to owners of the parent	71,696	70,180	(2.1)	—

Revenue by geographic areas for the first nine months is as follows:

(Unit: Millions of yen)

Geographic areas	For the nine months ended December 31, 2021	For the nine months ended December 31, 2022	Growth (%)	Growth excluding impact of FX translations (%)
Japan	155,034	157,044	1.3	1.3
Europe	103,997	118,615	14.1	4.6
Americas	161,219	212,363	31.7	8.1
China	44,605	56,628	27.0	8.6
Asia and others	58,625	73,341	25.1	10.2
Overseas total	368,447	460,948	25.1	7.5
Total	523,482	617,993	18.1	5.6

Revenue

Revenue totaled ¥618.0 billion, an increase of 18.1% versus the same period in the previous fiscal year.

In Japan, overall revenue increased by 1.3% year on year, amid strong revenue from Pharmaceutical Solutions division, which pursues alliance business with pharmaceutical companies, and Hospital Care Solutions division in the surgical field, despite a delayed recovery in medical demand due to the eighth wave of the COVID-19 pandemic.

Revenue overseas increased by 25.1% year on year owing to double digit growth across all companies centered on TIS (catheter) division because of the steady recovery in medical demand.

Profit

Gross profit totaled ¥318.3 billion, an increase of 14.2% versus the same period in the previous fiscal year, because the effects of higher revenue and hikes to selling prices partially offset increases in manufacturing costs caused by inflation.

Adjusted operating profit was ¥109.6 billion, an increase of 2.3% versus the same period in the previous fiscal year. This was attributed to stricter measures to control costs which partially offset the increase in selling, general and administrative expenses resulting from yen weakness.

Operating profit, profit before tax, and profit for the period attributable to owners of the parent each declined due to such impacts as increased amortization expense for acquired intangible assets, an adjustment item, caused by yen weakness.

Adjusted operating profit is a non-IFRS performance indicator that we disclose. Adjusted operating profit factors out amortization expense for intangible assets obtained during acquisitions and one-off income and expenses from operating profit. In addition, adjusted operating profit is consistent with segment profit.

Adjusted operating profit is being used as an indicator for corporate management to grasp earnings performance in each business as a part of our goal to achieve sustainable growth in the mid- to long-term. We believe this is also effective data for individuals using our financial statements to assess the Terumo Group's earnings.

Revenue results of the reportable segments are as follows:

The reportable segment which was previously named “General Hospital Company” was changed to “Medical Care Solutions Company” from the previous fiscal year. This change in name does not affect the segment information. In accordance with this change, the name of the reportable segment for the nine months ended December 31, 2021 was also changed to “Medical Care Solutions Company”.

(Unit: Millions of yen)

Segment		For the nine months ended December 31, 2021	For the nine months ended December 31, 2022	Growth (%)	Growth excluding impact of FX translations (%)
Cardiac and Vascular Company	Revenue	294,403	358,907	21.9	6.2
	(Japan)	38,478	38,379	(0.3)	(0.3)
	(Overseas)	255,924	320,528	25.2	7.2
Medical Care Solutions Company	Revenue	138,733	145,511	4.9	1.7
	(Japan)	107,664	110,149	2.3	2.3
	(Overseas)	31,069	35,361	13.8	(0.4)
Blood and Cell Technologies Company	Revenue	90,154	113,388	25.8	10.0
	(Japan)	8,700	8,329	(4.3)	(4.3)
	(Overseas)	81,453	105,058	29.0	11.5

Cardiac and Vascular Company

In Japan, overall revenue declined slightly year on year as the recovery in medical demand lagged due to the impacts of the eighth wave of COVID-19. Despite this, Vascular Graft division posted a substantial increase in revenue from the launch of new products. Overseas, revenue increased 25.2% year on year amid the recovery and growth of medical demand as well as strong sales across all divisions underpinned by the new products of Vascular Graft division. Global revenue increased 21.9% over the same period of the previous fiscal year to ¥358.9 billion.

Medical Care Solutions Company

In Japan, revenue increased by 2.3% year on year due to the solid sales of Pharmaceutical Solutions division and adhesion barrier product in Hospital Care Solutions division, despite the lagging recovery in medical demand. Overseas, revenue was strong, up 13.8% year on year. Global revenue increased 4.9% over the same period of the previous fiscal year to ¥145.5 billion.

Blood and Cell Technologies Company

In Japan, sales declined year on year, impacted by the lagging recovery in medical demand. Overseas, revenue increased substantially by 29.0% year on year, driven by the recovery in blood transfusion demand in Asia and other regions as well as strong demand for blood component collection systems in North America. Global revenue increased 25.8% over the same period of the previous fiscal year to ¥113.4 billion.

(2) Overview of Consolidated Statement of Financial Position

Total assets stood at ¥1,543.5 billion, an increase of ¥69.8 billion. This was mainly owing to an increase in inventories of ¥38.5 billion due to the impacts of yen weakness in foreign exchange rates, as well as property, plant and equipment of ¥22.9 billion and goodwill and intangible assets of ¥21.7 billion due to the aforementioned foreign exchange rates impact and investment in manufacturing facility and new IT systems, which offset the decrease in cash and cash equivalents of ¥42.9 billion from acquisition of treasury share. Total liabilities came to ¥469.8 billion, an increase of ¥8.4 billion. This was mainly attributed to the increase in bonds and borrowings of ¥5.7 billion due to the aforementioned foreign exchange rates impact. Total equity was ¥1,073.7 billion, an increase of ¥61.4 billion. This mainly reflects an increase from posting profit for the period of ¥70.2 billion, while the booking of other comprehensive income associated with the aforementioned foreign exchange rates impact resulted in a ¥69.0 billion increase, which offset the decrease of ¥50.1 billion from the acquisition of treasury shares and the decrease of ¥27.9 billion from dividends from retained earnings.

(3) Forecasts, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2023

At present, we must continue to monitor risks such as uncertainty about subsequent waves of COVID-19 infections and other impacts caused by the infections, such as a drop in demand, supply chain disruptions, rising manufacturing costs, and reduced operation levels at the plants, etc. Nevertheless, we plan to focus on development, launch, and expansion of highly value-added products and solutions that will boost the quality and efficiency of healthcare, along with further improvement to manufacturing costs, and effective use of selling, general and administrative expenses.

2. Condensed Consolidated Financial Statements

(1) Condensed Consolidated Statement of Financial Position

	(Unit: Millions of yen)	
	As of March 31, 2022	As of December 31, 2022
Assets		
Current assets		
Cash and cash equivalents	205,251	162,388
Trade and other receivables	135,998	154,063
Other current financial assets	63	240
Inventories	198,536	237,071
Current tax assets	778	2,536
Other current assets	18,086	18,490
Total current assets	558,713	574,791
Non-current assets		
Property, plant and equipment	333,864	356,716
Goodwill and intangible assets	514,801	536,502
Investments accounted for using the equity method	4,133	3,644
Other non-current financial assets	25,937	34,627
Deferred tax assets	20,198	21,589
Other non-current assets	16,043	15,597
Total non-current assets	914,979	968,678
Total assets	1,473,693	1,543,470

	(Unit: Millions of yen)	
	As of March 31, 2022	As of December 31, 2022
Liabilities and Equity		
Liabilities		
Current liabilities		
Trade and other payables	81,545	83,787
Bonds and borrowings	1,121	11,214
Other current financial liabilities	7,228	7,262
Current tax liabilities	14,104	18,362
Provisions	499	354
Other current liabilities	73,222	74,713
Total current liabilities	177,721	195,695
Non-current liabilities		
Bonds and borrowings	224,875	220,492
Other non-current financial liabilities	30,297	29,175
Deferred tax liabilities	12,746	10,160
Retirement benefit liabilities	5,811	5,171
Provisions	113	125
Other non-current liabilities	9,813	8,937
Total non-current liabilities	283,658	274,063
Total liabilities	461,379	469,758
Equity		
Share capital	38,716	38,716
Capital surplus	51,921	51,937
Treasury shares	(6,229)	(56,020)
Retained earnings	846,978	891,992
Other components of equity	80,926	147,085
Total equity attributable to owners of the parent	1,012,313	1,073,711
Total equity	1,012,313	1,073,711
Total liabilities and equity	1,473,693	1,543,470

(2) Condensed Consolidated Statement of Profit or Loss and Condensed Consolidated Statement of Comprehensive Income

(Condensed Consolidated Statement of Profit or Loss)

(Unit: Millions of yen)

	For the nine months ended December 31, 2021	For the nine months ended December 31, 2022
Revenue	523,482	617,993
Cost of sales	244,641	299,646
Gross profit	278,841	318,347
Selling, general and administrative expenses	183,738	224,136
Other income	1,814	8,226
Other expenses	2,461	8,922
Operating profit	94,455	93,514
Finance income	759	1,915
Finance costs	2,603	3,466
Share of profit/(loss) of investments accounted for using the equity method	433	136
Profit before tax	93,044	92,100
Income tax expenses	21,348	21,920
Profit for the period	71,696	70,180
Attributable to:		
Owners of the parent	71,696	70,180
Total profit for the period	71,696	70,180
Earnings per share		
Basic earnings per share (yen)	94.82	93.25
Diluted earnings per share (yen)	94.76	93.21

(Condensed Consolidated Statement of Comprehensive Income)

	(Unit: Millions of yen)	
	For the nine months ended December 31, 2021	For the nine months ended December 31, 2022
Profit for the period	71,696	70,180
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Changes in financial assets measured at fair value through other comprehensive income	106	1,982
Remeasurements of defined benefit plans	15	864
Total items that will not be reclassified to profit or loss	121	2,847
Items that are or may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	30,018	65,723
Cash flow hedges	228	734
Cost of hedging	(20)	(341)
Total items that are or may be reclassified subsequently to profit or loss	30,227	66,117
Total other comprehensive income/(loss) for the period	30,348	68,964
Total comprehensive income for the period	102,045	139,144
Attributable to:		
Owners of the parent	102,045	139,144
Total comprehensive income for the period	102,045	139,144

(Note) Items in the above statement are net of tax.

(3) Condensed Consolidated Statement of Changes in Equity

(Unit: Millions of yen)

	Equity attributable to owners of the parent					Total	Total equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		
Balance as of April 1, 2021	38,716	51,829	(6,838)	775,078	(2,123)	856,662	856,662
Profit for the period	—	—	—	71,696	—	71,696	71,696
Other comprehensive income	—	—	—	—	30,348	30,348	30,348
Total comprehensive income	—	—	—	71,696	30,348	102,045	102,045
Acquisition of treasury shares	—	—	(2)	—	—	(2)	(2)
Disposal of treasury shares	—	(5)	33	—	(27)	0	0
Dividends	—	—	—	(23,440)	—	(23,440)	(23,440)
Transfer from other components of equity to retained earnings	—	—	—	(156)	156	—	—
Share-based payments	—	62	91	—	26	180	180
Conversion of convertible bonds	—	(11)	470	—	—	459	459
Total transactions with owners of the parent	—	45	592	(23,597)	156	(22,803)	(22,803)
Balance as of December 31, 2021	38,716	51,874	(6,245)	823,177	28,381	935,904	935,904

(Unit: Millions of yen)

	Equity attributable to owners of the parent					Total	Total equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		
Balance as of April 1, 2022	38,716	51,921	(6,229)	846,978	80,926	1,012,313	1,012,313
Profit for the period	—	—	—	70,180	—	70,180	70,180
Other comprehensive income	—	—	—	—	68,964	68,964	68,964
Total comprehensive income	—	—	—	70,180	68,964	139,144	139,144
Acquisition of treasury shares	—	(56)	(50,002)	—	—	(50,058)	(50,058)
Disposal of treasury shares	—	17	87	—	(105)	0	0
Dividends	—	—	—	(27,924)	—	(27,924)	(27,924)
Transfer from other components of equity to retained earnings	—	—	—	2,758	(2,758)	—	—
Share-based payments	—	54	123	—	57	235	235
Total transactions with owners of the parent	—	15	(49,791)	(25,165)	(2,805)	(77,747)	(77,747)
Balance as of December 31, 2022	38,716	51,937	(56,020)	891,992	147,085	1,073,711	1,073,711

(4) Notes Pertaining to Condensed Consolidated Financial Statements

(i) Going concern assumption

Not applicable

(ii) Segment information

(1) General information on reportable segments

The reportable segments of the Group represent business units for which separate financial information is available, and are reviewed regularly at the Board of Directors meeting to make decisions about allocation of management resources and assess the performance of the business.

The Group applies an in-house company system classified by product groups. The headquarter of each in-house company plans their own comprehensive domestic and international strategies and conducts their own business activities.

The three segments are Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

The segment which was previously stated as “General Hospital Company” has been changed to “Medical Care Solutions Company” from the fiscal year ended March 31, 2022. This change in name does not affect the segment information. In accordance with this change, the name of the reportable segment for the nine months ended December 31, 2021 was also changed to “Medical Care Solutions Company”.

(2) Reportable segment information

Revenue and operating results of the reporting segments of the Group are described below.

For the nine months ended December 31, 2021

(Unit: Millions of yen)

	Reportable Segments			Total	Adjustments (Note 1)	Amount recorded on condensed consolidated financial statements
	Cardiac and Vascular Company	Medical Care Solutions Company	Blood and Cell Technologies Company			
Revenue						
Revenue from sales to external customers	294,403	138,733	90,154	523,291	190	523,482
Segment profit (Adjusted operating profit)	72,326	19,345	17,191	108,862	(1,705)	107,157
(Adjustment item)						
Amortization of intangible assets acquired through business combinations	(5,496)	—	(6,294)	(11,791)	(50)	(11,841)
Non-recurring profit or loss(Note 2)						(860)
Operating profit						94,455
Finance income						759
Finance costs						(2,603)
Share of profit/(loss) of investment accounted for using the equity method						433
Profit before tax						93,044

(Note 1) Amounts in “Adjustments” are as follows:

- (1) ¥190 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments.
 - (2) ¥(1,705) million adjustment to Segment profit consists of ¥(85) million for inventories and ¥(1,962) million for preparation expenses to comply with Medical Device Regulation in EU.
- (Note 2) ¥(860) million Non-recurring profit or loss mainly includes ¥(213) million for the change in fair value of contingent consideration and ¥(645) million for business reorganization expenses.

For the nine months ended December 31, 2022

(Unit: Millions of yen)

	Reportable Segments			Total	Adjustments (Note 1)	Amount recorded on condensed consolidated financial statements
	Cardiac and Vascular Company	Medical Care Solutions Company	Blood and Cell Technologies Company			
Revenue						
Revenue from sales to external customers	358,907	145,511	113,388	617,807	186	617,993
Segment profit (Adjusted operating profit)	83,598	12,605	12,924	109,127	479	109,607
(Adjustment item)						
Amortization of intangible assets acquired through business combinations	(6,770)	—	(7,633)	(14,403)	4	(14,399)
Non-recurring profit or loss(Note 2)						(1,694)
Operating profit						93,514
Finance income						1,915
Finance costs						(3,466)
Share of profit/(loss) of investment accounted for using the equity method						136
Profit before tax						92,100

(Note 1) Amounts in “Adjustments” are as follows:

- (1) ¥186 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments.
- (2) ¥479 million adjustment to Segment profit consists of ¥(2,511) million for preparation expenses to comply with Medical Device Regulation in EU and ¥(359) million for inventories.

(Note 2) ¥(1,694) million Non-recurring profit or loss mainly includes ¥(1,788) million for impairment loss of technologies, ¥(3,589) million for impairment loss of goodwill, ¥(1,564) million for business reorganization expenses, ¥1,357 million for the change in fair value of contingent consideration and ¥3,891 million for gain on business transfer and other.

(iii) Impairment of non-financial assets

In the nine months ended December 31, 2022, impairment losses of ¥5,377 million recorded are as follows.

(1) Impairment loss of the Autologous Biologics business unit in Blood and Cell Technologies Company

Autologous Biologics business unit was classified as assets held for sale and directly related liabilities in the nine months ended December 31, 2022, based on the transfer agreement with Globus Medical, Inc. As the disposal group classified as assets held for sale is measured at fair value less cost to sell, an impairment loss of ¥3,589 million was recorded.

The fair value was determined based on the expected selling price in the transfer agreement with Globus Medical, Inc. and this fair value has been classified as Level 3 in the hierarchy.

The impairment loss recognized on “Goodwill and intangible assets” is included in "Other expenses" in the Condensed Consolidated Statement of Profit or Loss. The transfer of the business was completed on October 11, 2022.

(2) Impairment loss of certain technologies in intangible assets in Cardiac and Vascular Company

In the nine months ended December 31, 2022, ¥1,788 million for an impairment loss of certain technologies in intangible assets was recorded with the decision for discontinuing a portion of product.

The recoverable amount was measured based on the value in use, and the value was determined to be zero. The impairment loss is included in “Other expenses” in the Condensed Consolidated Statement of Profit or Loss.

(iv) Subsequent events

Cancellation of treasury shares

The Company resolved to cancel treasury shares at the Board of Directors meeting held on May 12, 2022 pursuant to the provisions of Article 178 of the Companies Act. The treasury shares were canceled on January 13, 2023.

1. Class of stock canceled: the Company’s common stock
2. Number of shares canceled: 11,838,500 shares
3. Total number of outstanding shares after cancellation: 747,682,540 shares
4. Date of cancellation: January 13, 2023